New Cambridge House, Bassingbourn Road
About Cresset GroupCresset was formed in 2002 by Dr Andy Vinter. His ground breaking research on new virtual screening technology formed the scientific foundation of the company and has underpinned our technical development ever since. Andy continues to work alongside our leadership team and R&D team to innovate and extend the scientific base of the company, inspiring us as we grow.
Founder: Andy Vinter
Founder and CSO: Mart Mackey
CEO: Robert Scoffin
Please click here for Cresset job opportunities.
Tweets by Cresset
42 articles with Cresset Group
7/31/2020Biopharma and life science companies strengthen their leadership teams and board with these Movers & Shakers.
Flare™ V2 heralds next generation of structure-based design with Electrostatic Complementarity™ scoring and new Python® API
Cresset is pleased to announce the release of Flare V2. Introducing major enhancements to ligand design and activity prediction in a modern, extensible, scriptable interface, Flare V2 raises the bar in structure-based design.
Cresset is pleased to announce that Proximagen, a drug discovery and development company, has licensed Flare.
Cresset Group Applications Licensed By Shiv Nadar University, India, To Teach Computational Chemists Of The Future
Cresset Group Release: Scientific Program And Workshops Announced For The Cresset User Group Meeting, 29th – 30th June 2017, Cambridge, UK
Peakdale Molecular Ltd. Extends Its Offering By Signing Collaborative Agreement With Computational Chemistry Company, Cresset Group
Cresset Group's New Activity Miner for Lead Optimization Highlights and Explains Key Activity Insights
Victrix CMCC Chooses Cresset Group's Software for Drug Discovery Consulting Projects to Give Insight Into Molecular Activity
Cresset Group Chemistry Software Available Free to Degree Students and at Low Cost to Academic Researchers
Cresset Group Release: Biologically Intelligent Database Searching for Lead Identification and Patent Fortification
Cresset Group Release: sparkV10 Chosen to Facilitate the Hit Optimization Process in ProMining Therapeutics